Objective:
To evaluate the safety and effectiveness of bioreinforced cyclodialysis with scleral allograft in managing primary open-angle glaucoma (POAG) during cataract surgery.
Key Findings:
- Mean medicated IOP reduced from 19.5±4.9 mmHg to 14.6±6.7 mmHg at 24 months.
- Mean number of IOP-lowering medications decreased from 1.61±1.4 to 0.70±0.81.
- Statistically significant and clinically meaningful reductions in IOP and medication use were observed.
Interpretation:
The bioreinforced cyclodialysis procedure shows promise in effectively lowering IOP in POAG patients while reducing the need for medications, with an acceptable safety profile.
Limitations:
- Long-term outcomes beyond 24 months are not yet available.
- The study's sample size may limit generalizability.
Conclusion:
The bioreinforced cyclodialysis procedure represents a potential advancement in glaucoma management, enhancing uveoscleral outflow with a favorable safety profile.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.